BostonGene

We are proud to announce that BostonGene has been recognized with five awards in the 2024 Pharmaceutical Technology Excellence Awards by GlobalData Healthcare —honored in Business Expansion, Research and Development, Innovation, Product Launches and Marketing. "BostonGene’s accomplishments reflect the power of AI in revolutionizing cancer care and patient outcomes. These awards highlight BostonGene’s pivotal role in reshaping cancer diagnostics and treatment, demonstrating how cutting-edge technology can accelerate and enhance patient-centric solutions in the pharmaceutical landscape." - Tina Ross, Global Awards Manager at GlobalData Read more: https://lnkd.in/ev8-777V

We're ready! Join us this week at #SITC24! Stop by booth #514!

Join us this week at #SITC24! Discover how BostonGene's technology is advancing cancer treatment strategies, from deep molecular insights to predictive biomarkers. Visit us at Booth #514.

Join us this week at #SITC24, where we will present six studies showcasing advancements in AI-powered tumor microenvironment profiling, genomic analysis, biomarker identification, immune-related adverse event prediction and novel drug targeting, paving the way for precision oncology. Learn more: https://lnkd.in/g2mfp3yJ

Meet us next week at #PathVisions24! “Pathology Visions offers a dynamic platform for driving progress in digital pathology. The conference brings together diverse experts from around the world. I’m excited to moderate the discussion on advancing regulatory science. Collaborative efforts between industry, academia, and regulatory bodies are essential to accelerate digital pathology adoption in the U.S. This conference is a valuable opportunity to share insights, explore innovative solutions and shape the future of pathology for better patient care.” - Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene. Learn more: https://lnkd.in/ebZSTREf

Join us this week at the APM Annual Conference 2024! During the event, Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene, will participate in a panel session highlighting scalable solutions for enhancing access to precision medicine and reducing care disparities through guidelines and network-based approaches. “At APM 2024, we’re excited to explore practical solutions for expanding precision medicine’s reach in cancer care. This session will highlight how network-based approaches can improve diagnostic access in underserved areas, reducing treatment disparities and advancing precision medicine for all patients.” - Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene Learn more: https://lnkd.in/e6BnPfTZ

The BostonGene team had an outstanding experience at the 31st Prostate Cancer Foundation scientific retreat in Carlsbad, CA. We were thrilled to introduce our solutions for patients, including our immune system profiling platform to this phenomenal group of physicians, scientists, drug developers, and philanthropists that are striving to produce better outcomes for prostate cancer patients.

Join us for the @sitcancer Annual Meeting! Be part of the #SITC24 experience!

Join us this week in Barcelona for #ENA2024! During the event, Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene will deliver a presentation discussing the crucial role of regulatory oversight in shaping laboratory-developed tests, highlighting challenges and solutions to improve accuracy, reliability and patient safety.  “We are eager to share our insights on the regulatory landscape and the importance of biomarkers in shaping the future of cancer therapeutics. The presentation will underscore the need for robust regulatory frameworks to support innovation, speed up drug discovery and ultimately enhance patient outcomes in this rapidly evolving field.” - Joe Lennerz Learn more: https://lnkd.in/gkbBeNg2

We're pleased to announce that Fujita Health University Haneda Clinic will now offer genomic profile testing for cancer patients using the BostonGene Tumor Portrait™ test. By predicting the efficacy of immune checkpoint inhibitors, the Tumor Portrait™ supports more effective treatment selection, reducing unnecessary interventions and side effects. This collaboration marks a significant step forward in precision medicine, ensuring that more patients can benefit from tailored therapies that improve outcomes and enhance quality of life. Read more: https://lnkd.in/exaRxNFb